This article is more than 5 years old. Information may no longer be current.
ACR issues statement on new FDA Commissioner Scott Gottlieb
Click Here to Manage Email Alerts
The American College of Rheumatology has issued a statement regarding the confirmation of Scott Gottlieb as commissioner of the FDA, according to a press release.
“The ACR congratulates Dr. Scott Gottlieb on his confirmation as FDA commissioner,” Sharad Lakhanpal, MBBS, MD, president of the American College of Rheumatology (ACR), said. “As prescribing doctors, rheumatologists share Commissioner Gottlieb’s goal of optimizing FDA biosimilar and generic drug approvals to increase competition, lower costs and improve our patients’ access to safe and proven therapies.”
Lakhanpal also mentioned support for adequate funding of the FDA to help biosimilar drug approvals.
“The FDA continues to play a critical role in lowering biologic drug costs as it works to bring safe, effective and lower-cost biosimilar alternatives to the marketplace,” Lakhanpal said. “Therefore, it is imperative that FDA have the funding and resources it needs to expedite biosimilar drug approvals, hire and retain qualified staff, issue guidance and perform adequate post-market surveillance. We look forward to working with Commissioner Gottlieb, Congressional leaders and the Trump administration to bolster the FDA’s important work on biosimilars to ensure more Americans can access safe, effective and life-changing therapies.”
Reference: